Literature DB >> 17107914

Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sites.

Rosana B Michel1, Mones Abu-Asab, Maria Tsokos, M Jules Mattes.   

Abstract

Antibodies (Abs) to CD20 or HLA-DR, after binding to the B-lymphoma cell line RL following an overnight incubation at 37 degrees C, accumulate in the form of shed vesicles, which develop in the center of the cell clusters that are spontaneously formed by this cell line. These vesicles coalesce into fairly stable large structures, which we refer to as conglomerates of shed vesicles (CSVs). In the present study, we have extended our previous investigations into the nature of this material. Electron microscopy revealed a conglomerate of heterogeneous vesicles, which looked like pinched-off cytoplasmic projections. CSVs developed similarly either with or without Ab, demonstrating that CSV production is a spontaneous process that incorporates bound Abs if they are present. Before delivery to CSVs, the Abs capped on the cell surface. CSVs had high expression of annexin V binding sites, which are phagocytic signals that are exposed on damaged cells. For CSVs that were cell bound, which are frequently observed, the annexin V binding sites were only in the CSVs, and not on the surface of the intact cell. Although all CSVs contained both Abs and annexin V binding sites, the precise distribution of these two ligands was generally different. Annexin V binding sites were present on caps as well as on CSVs, and appear as soon as caps are formed. In cells incubated with anti-HLA-DR, CD20 was delivered to the CSVs together with HLA-DR, suggesting an association between these two molecules. CSVs prepared with anti-HLA-DR, but not CSVs prepared with anti-CD20, contained considerable numbers of nuclear fragments, identified by propidium iodide staining.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17107914      PMCID: PMC2366172          DOI: 10.1080/10428190600783494

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  23 in total

1.  Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.

Authors:  K S Brown; D J Levitt; M Shannon; B K Link
Journal:  Clin Lymphoma       Date:  2001-12

2.  Blebs and apoptotic bodies are B cell autoantigens.

Authors:  Brian A Cocca; Amy M Cline; Marko Z Radic
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

3.  Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells.

Authors:  Rosana B Michel; M Jules Mattes
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

Review 4.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

5.  CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

Authors:  H T Claude Chan; David Hughes; Ruth R French; Alison L Tutt; Claire A Walshe; Jessica L Teeling; Martin J Glennie; Mark S Cragg
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

6.  Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation.

Authors:  S R Dillon; M Mancini; A Rosen; M S Schlissel
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

7.  Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Authors:  Pina M Cardarelli; Maire Quinn; Dana Buckman; Yu Fang; David Colcher; David J King; Christopher Bebbington; Geoffrey Yarranton
Journal:  Cancer Immunol Immunother       Date:  2001-12-18       Impact factor: 6.968

8.  Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules.

Authors:  H F Heijnen; A E Schiel; R Fijnheer; H J Geuze; J J Sixma
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

9.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

10.  Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.

Authors:  Zoltan A Nagy; Bernd Hubner; Corinna Löhning; Robert Rauchenberger; Silke Reiffert; Elisabeth Thomassen-Wolf; Stefan Zahn; Sigmar Leyer; Eva M Schier; Angelika Zahradnik; Christoph Brunner; Kurt Lobenwein; Benno Rattel; Michael Stanglmaier; Michael Hallek; Mark Wing; Steve Anderson; Matt Dunn; Titus Kretzschmar; Michael Tesar
Journal:  Nat Med       Date:  2002-07-08       Impact factor: 53.440

View more
  2 in total

1.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

2.  Apoptosis assays with lymphoma cell lines: problems and pitfalls.

Authors:  M J Mattes
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.